Shionogi & Co., Ltd.
Shionogi & Co., Ltd. Q1 Financial Summary (IFRS) for the Fiscal Year Ending March 2027 | April 1, 2026 to June 30, 2026
In the cumulative first quarter of the fiscal year ending March 2027, net sales/ revenue reached 163,310 million yen (up 63.7% YoY), operating income 66,911 million yen (up 90.6% YoY), and net income attributable to owners of the parent 97,696 million yen (up 148.2% YoY), achieving a new high. Finance was significantly boosted by consolidation effects from the Edarabon business succession, the consolidation of Torii Pharmaceutical, and transactions related to the equity-method accounting for ViiV. Full-year guidance remains unchanged from the previous announcement. Cash decreased to 298,937 million yen. Main contributing factors include the consolidation of Torii Pharmaceutical, succession of the Edarabon business from田辺ファーマ (Tanabe Farm?), and related equity-method accounting for ViiV.
Key Figures
- Net sales / revenue: 163,310 百万円
- Operating income: 66,911 百万円
- Net income attributable to owners of the parent: 97,696 百万円
- Cash and cash equivalents: 298,937 百万円
- Acquired consideration (Torii Pharmaceutical, JT Pharmaceutical business, Akros, etc.) total: unknown (details described in the text)
AI要約
Business performance overview
For the first quarter of the consolidated fiscal year, net sales were 163,310 million yen, up 63.7% from 99,781 million yen in the same period last year. Increases were driven by domestic pharmaceuticals and overseas subsidiaries/export royalty income. The Edarabon business succession, the consolidation of Torii Pharmaceutical, and the application of equity-method accounting for ViiV Healthcare had significant effects on performance, with substantial increases in operating income, ordinary income, and net income attributable to owners of the parent. Cash on hand decreased. Full-year guidance remains unchanged from the previous announcement.
Outlook and impact
The earnings forecast for this year remains unchanged from the May 2026 release. Ongoing corporate actions, including the Edarabon business succession from Tanabe Pharma, the acquisition of Torii Pharmaceutical and succession of the JT Pharmaceutical business, and the acquisition of Akros’ shares, are expected to continue impacting results. The accounting treatment for investments subject to the equity method and retrospective adjustments arising from provisional accounting could affect future figures.
Shionogi & Co., Ltd.
Company overview · Stock price · Financial data · All IR
